Question 1

What is Nilotinib?

Accepted Answer

Nilotinib belongs to a class of drugs known as kinase inhibitors . It works by blocking the action of specific proteins that signal cancer cells to multiply and divide.

By targeting these proteins, the medication helps to slow or stop the growth of abnormal cells in the body. This action helps manage the progression of the condition at a cellular level.

Question 2

What is Nilotinib used for?

Accepted Answer

Nilotinib is used to treat Philadelphia chromosome-positive chronic myeloid leukemia .

Question 3

How does Nilotinib work?

Accepted Answer

Targeting Cancer Cells

Nilotinib is a type of targeted therapy known as a kinase inhibitor. It works by interfering with the signals that tell cancer cells to grow and divide. Specifically, it targets a protein called BCR-ABL.

This protein is created by the Philadelphia chromosome, which is an abnormal gene found in the leukemia cells of people with certain types of chronic myeloid leukemia (CML). The BCR-ABL protein acts as a signal that causes the bone marrow to produce too many abnormal white blood cells.

When nilotinib enters the body, it blocks the BCR-ABL protein from sending these signals. By blocking this protein, the medication helps to:

Stop the uncontrolled growth of leukemia cells.

Reduce the number of abnormal white blood cells in the bloodstream.

Slow the progression of the cancer.

Because nilotinib is a targeted therapy, it is designed to focus on the specific proteins that allow cancer cells to thrive, rather than affecting all rapidly dividing cells in the body.

Question 4

What are the brand names for Nilotinib?

Accepted Answer

Nilotinib is sold under the brand name Tasigna .

Question 5

What are the active ingredients in Nilotinib?

Accepted Answer

The active ingredient in Nilotinib is nilotinib .

Question 6

What are the side effects of Nilotinib?

Accepted Answer

Common side effects of Nilotinib may include:

Rash

Nausea

Headache

and others.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Nilotinib?

Accepted Answer

Nilotinib belongs to the tyrosine kinase inhibitor drug class.

Question 8

What is the dosage of Nilotinib and how do I take it?

Accepted Answer

How to Take Nilotinib

Nilotinib is taken by mouth, usually twice a day. The capsules should be swallowed whole with water. Do not crush, chew, or break the capsules.

Food and Timing

The relationship between nilotinib and food depends on the specific version of the medication you are taking. Many versions must be taken on an empty stomach. For these, do not eat for at least two hours before taking the dose and for at least one hour after taking it. Other versions may be taken with or without food.

Always follow the specific instructions provided by your healthcare provider or the medication label. If your version requires an empty stomach, avoid high-fat meals near your dosing time, as they can affect how the medicine is absorbed.

Missed Doses

If you miss a dose, skip the missed dose and take your next dose at the regular time. Do not take extra medicine to make up for a missed dose.

Special Instructions

Avoid grapefruit and grapefruit juice, as they can interfere with how the body processes the medication.

If you are unable to swallow capsules whole, consult your healthcare provider. Some versions may be opened and mixed with a small amount of applesauce and swallowed immediately, but this should only be done if specifically directed by a medical professional.

Question 9

Is Nilotinib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Nilotinib can cause fetal harm when administered to a pregnant woman. Healthcare providers typically require a pregnancy test before starting treatment to ensure the patient is not pregnant. If you are pregnant or planning to become pregnant, it is important to discuss the potential risks to the fetus with your medical team.

Contraception

Individuals who are able to become pregnant should use effective birth control during treatment with nilotinib. This contraception should be continued for at least 14 days after the final dose of the medication.

Breastfeeding

It is not known whether nilotinib passes into human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least 14 days after the last dose.

Question 10

What forms and strengths does Nilotinib come in?

Accepted Answer

Nilotinib is provided in the following oral dosage forms:

Capsules

Tablets

The different formulations of this medication may have different instructions regarding administration and food intake. It is important to follow the specific directions provided for the prescribed form, as some versions are taken on an empty stomach while others may have different requirements.

Question 11

What is the FDA approval status of Nilotinib?

Accepted Answer

FDA Approval Status

Nilotinib is approved by the U.S. Food and Drug Administration (FDA) for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Its approved uses include:

Newly diagnosed adults with Ph+ CML-CP.

Adults with Ph+ CML-CP who are resistant or intolerant to prior therapies, including imatinib.

Pediatric patients aged 1 year and older with newly diagnosed Ph+ CML-CP or those who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.

Boxed Warning

The FDA has issued a boxed warning for nilotinib due to the risk of QT interval prolongation, a heart rhythm abnormality that can lead to sudden death. Regulatory requirements for safe use include:

ECG Monitoring: Healthcare providers must perform an electrocardiogram (ECG) to monitor heart rhythm before starting treatment, seven days after starting, and periodically thereafter.

Electrolyte Correction: Patients must have normal blood levels of potassium and magnesium before starting nilotinib. These levels must be monitored and maintained during treatment.

Drug and Food Interactions: Nilotinib should not be taken with strong CYP3A4 inhibitors or certain foods, such as grapefruit products, which can increase drug levels and the risk of heart rhythm issues.

Dosing Requirements: To avoid dangerous increases in drug absorption, nilotinib must be taken on an empty stomach. Patients should not eat for at least two hours before and one hour after taking a dose.

Safety Communications

The FDA warns that nilotinib should not be used in patients with long QT syndrome or those with uncorrected low blood potassium or magnesium. Because of the potential for severe cardiovascular events, including arterial blockage, the FDA requires ongoing monitoring for signs of vascular issues and regular blood tests to check liver function and blood cell counts.

Question 12

What should I know about Nilotinib and fda?

Accepted Answer

FDA-Approved Indications

The U.S. Food and Drug Administration (FDA) has approved nilotinib for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the following populations:

Adults: For newly diagnosed chronic phase Ph+ CML, as well as chronic and accelerated phase Ph+ CML in patients who are resistant or intolerant to prior therapies.

Pediatric Patients: For children 1 year of age and older with newly diagnosed chronic phase Ph+ CML or those with chronic phase Ph+ CML who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.

Boxed Warning

The FDA has issued a boxed warning for nilotinib due to the risk of QT prolongation, a serious heart rhythm condition that can lead to sudden death. The FDA advises that the medication should not be used in patients with certain electrolyte imbalances, such as low blood levels of potassium or magnesium, or in those with long QT syndrome.

Regulatory History

Nilotinib received its initial FDA approval in 2007. In 2018, the FDA expanded the approval to include pediatric patients. In 2024, a new formulation of nilotinib was approved that provides different bioavailability, allowing for administration with or without food compared to the original formulation which requires fasting.

Nilotinib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Fda Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?